At Actio Biosciences, patients and families are at the center of everything we do.
Many of the diseases we study are rare, severe, and deeply impactful for the people who live with them. Our mission is to develop targeted medicines that address the underlying genetic drivers of disease, with the goal of improving outcomes for patients and their communities.
This section provides resources for patients, caregivers, and healthcare providers, including information about our clinical trials, educational materials about the conditions we study, and our policies for expanded access to investigational medicines.
Patient Resources
Actio Biosciences’ KCNT1-Related Epilepsy Patient Website
If you are interested in learning more about participating in the ABS-1230 Phase 1b/2 clinical trial, please visit ActioTrials.com, where you can find details about current studies, eligibility, and trial locations.
KCNT1 Epilepsy Foundation
For more information about KCNT1-related epilepsy, new therapies in development, the latest research information and resources for families and caregivers, please visit the KCNT1 Epilepsy Foundation website. The Foundation provides educational materials and a supportive community for families navigating this rare disease.
Expanded Access Policy
Our purpose at Actio Biosciences, Inc. is to develop new therapies that have a positive impact on patient health, and to serve patients, patient families and patient communities through education, empathy, and awareness. Read more…